Correction to: ECM1 regulates cell proliferation and trastuzumab resistance through activation of EGF-signaling (Breast Cancer Research (2014) 16:6 (479-495) DOI: 10.1186/s13058-014-0479-6);Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Lee, Kyung min ^a   Nam, Keesoo ^a   Oh, Sunhwa ^a   Lim, Juyeon ^a   Kim, Young Pil ^a   Lee, Won ^b   Yu, Jong Han ^b   Ahn, Sei Hyun ^b   Kim, Sung Bae ^b   Noh, Dong Young ^c   Lee, Taehoon ^d   Shin, Incheol ^a  

^a Hanyang University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d NOVACELL Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EXTRACELLULAR MATRIX PROTEIN 1; GALECTIN 3; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ECM1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; MESSENGER RNA; MMP9 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MUC1 PROTEIN, HUMAN; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TANDEM MASS SPECTROMETRY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ADENOCARCINOMA; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG RESISTANCE; GENETICS; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GALECTIN 3; HUMANS; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MICE, NUDE; MUCIN-1; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRASTUZUMAB;

EID: 84924249400     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-019-1106-3     Document Type: Erratum

References (53)

1. Mathieu E, Meheus L, Raymackers J, Merregaert J: Characterization of the osteogenic stromal cell line MN7: identification of secreted MN7 proteins using two-dimensional polyacrylamide gel electrophoresis, Western blotting, and microsequencing. J Bone Miner Res 1994, 9:903-913.
2. Smits P, Poumay Y, Karperien M, Tylzanowski P, Wauters J, Huylebroeck D, Ponec M, Merregaert J: Differentiation-dependent alternative splicing and expression of the extracellular matrix protein 1 gene in human keratinocytes. J Invest Dermatol 2000, 114:718-724.
3. Han Z, Ni J, Smits P, Underhill CB, Xie B, Chen Y, Liu N, Tylzanowski P, Parmelee D, Feng P, Ding I, Gao F, Gentz R, Huylebroeck D, Merregaert J, Zhang L: Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J 2001, 15:988-994.
4. Hamada T, McLean WH, Ramsay M, Ashton GH, Nanda A, Jenkins T, Edelstein I, South AP, Bleck O, Wessagowit V, Mallipeddi R, Orchard GE, Wan H, Dopping-Hepenstal PJ, Mellerio JE, Whittock NV, Munro CS, van Steensel MA, Steijlen PM, Ni J, Zhang L, Hashimoto T, Eady RAJ, McGrath JA: Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene ( ECM1 ). Hum Mol Genet 2002, 11:833-840.
5. Wang L, Yu J, Ni J, Xu XM, Wang J, Ning H, Pei XF, Chen J, Yang S, Underhill CB, Liu L, Liekens J, Merregaert J, Zhang L: Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Lett 2003, 200:57-67.
6. Lal G, Hashimi S, Smith BJ, Lynch CF, Zhang L, Robinson RA, Weigel RJ: Extracellular matrix 1 ( ECM1 ) expression is a novel prognostic marker for poor long-term survival in breast cancer: a hospital-based cohort study in Iowa. Ann Surg Oncol 2009, 16:2280-2287.
7. Wu QW: She HQ, Liang J, Huang YF, Yang QM, Yang QL, Zhang ZM: Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. BMC Cancer 2012, 12:47.
8. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285-4289.
9. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-4141.
10. Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Therapeut 1999, 21:309-318.
11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
12. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13:4909-4919.
13. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B: Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to herceptin. Cancer Res 2010, 70:1204-1214.
14. kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004, 64:3981-3986. A published erratum appears in Cancer Res 2008, 68:10005.
15. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
16. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
17. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005, 65:473-482.
18. Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br J Cancer 2011, 105:1176-1182.
19. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, Wu Y, Price JE, Tan M: Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011, 71:4585-4597.
20. Oliveras-Ferraros C, Corominas-Faja B, Cufi S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, López-Bonet E, Martin ÁG, Menendez JA: Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 2012, 11:4020-4032.
21. Park S, Lee KM, Ju JH, Kim J, Noh DY, Lee T, Shin I: Protein expression profiling of primary mammary epithelial cells derived from MMTV- neu mice revealed that HER2/NEU-driven changes in protein expression are functionally clustered. IUBMB Life 2010, 62:41-50.
22. Lee GY, Park K, Kim SY, Byun Y: MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm 2007, 67:646-654.
23. Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, El-Yazidi-Belkoura I, Nurcombe V, Peyrat JP: Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 2001, 1:1216-1232.
24. Kaplan-Meier Plotter Breast Cancer. [http://kmplot.com/breast ]
25. Mongiat M, Fu J, Oldershaw R, Greenhalgh R, Gown AM, Iozzo RV: Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem 2003, 278:17491-17499.
26. 1 . Nat Immunol 2011, 12:178-185.
27. Merlin J, Stechly L, de Beauce S, Monte D, Leteurtre E, van Seuningen I, Huet G, Pigny P: Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011, 30:2514-2525.
28. Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, Yu LG: Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res 2009, 69:6799-6806.
29. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ: Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001, 276:13057-13064.
30. Pochampalli MR, el Bejjani RM, Schroeder JA: MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007, 26:1693-1701.
31. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994, 33:14109-14114.
32. Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A: Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res 2007, 67:11760-11768.
33. Sato H, Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993, 8:395-405.
34. Savorè C, Zhang C, Muir C, Liu R, Wyrwa J, Shu J, Zhau HE, Chung LW, Carson DD, Farach-Carson MC: Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis 2005, 22:377-390.
35. Radke S, Austermann J, Russo-Marie F, Gerke V, Rescher U: Specific association of annexin 1 with plasma membrane-resident and internalized EGF receptors mediated through the protein core domain. FEBS Lett 2004, 578:95-98.
36. Hu Y, Gao H, Vo C, Ke C, Pan F, Yu L, Siegel E, Hess KR, Linskey ME, Zhou YH: Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis. Oncoscience 2014, 1:205-215.
37. Sercu S, Zhang M, Oyama N, Hansen U, Ghalbzouri AE, Jun G, Geentjens K, Zhang L, Merregaert JH: Interaction of extracellular matrix protein 1 with extracellular matrix components: ECM1 is a basement membrane protein of the skin. J Invest Dermatol 2008, 128:1397-1408.
38. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011, 108:5021-5026.
39. Liu W, Hsu DK, Chen HY, Yang RY, Carraway KL 3rd, Isseroff RR, Liu FT: Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration. J Invest Dermatol 2012, 132:2828-2837.
40. Hisatsune A, Nakayama H, Kawasaki M, Horie I, Miyata T, Isohama Y, Kim KC, Katsuki H: Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem Biophys Res Commun 2011, 405:377-381.
41. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D: Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 2014, 33:3422-3431.
42. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S: Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000, 6:1389-1393.
43. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM: Tagliabue E: microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009, 69:2195-2200.
44. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A: Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010, 127:2530-2541.
45. Fujimoto N, Terlizzi J, Aho S, Brittingham R, Fertala A, Oyama N, McGrath JA, Uitto J: Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions. Exp Dermatol 2006, 15:300-307.
46. Xiong GP, Zhang JX, Gu SP, Wu YB, Liu JF: Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell. Neoplasma 2012, 59:409-415.
47. Chattopadhyay S, Shubayev VI: MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway. Glia 2009, 57:1316-1325.
48. 1 permutations. Bioorg Med Chem Lett 2008, 18:560-564.
49. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortés-Funes H, Lloveras B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000, 6:2356-2362.
50. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase 3β-mediated phosphorylation and degradation of β-catenin. Cancer Res 2005, 65:10413-10422.
51. Cascio S, Zhang L, Finn OJ: MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. J Biol Chem 2011, 286:42248-42256.
52. Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R, Kufe D: MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 2014, 33:1680-1689.
53. Gu M, Guan J, Zhao L, Ni K, Li X, Han Z: Correlation of ECM1 expression level with the pathogenesis and metastasis of laryngeal carcinoma. Int J Exp Pathol 2013, 6:1132-1137.